p53 Activation Effect in the Balance of T Regulatory and Effector Cell Subsets in Patients With Thyroid Cancer and Autoimmunity
| العنوان: | p53 Activation Effect in the Balance of T Regulatory and Effector Cell Subsets in Patients With Thyroid Cancer and Autoimmunity |
|---|---|
| المؤلفون: | Maria Rita Assenza, Alessandra Fierabracci, Maria Manuela Rosado, Armando Grossi, Eugenia Belcastro, Fabiola Moretti, Antonio Stigliano, Ezio Giorda, Andrea Arena |
| المصدر: | Frontiers in Immunology Frontiers in Immunology, Vol 12 (2021) |
| بيانات النشر: | Frontiers Media S.A., 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | p53, Adult, Male, medicine.medical_treatment, T regulatory cells, Immunology, Programmed Cell Death 1 Receptor, Antineoplastic Agents, Autoimmunity, medicine.disease_cause, T effector cells, immunotherapy, pediatric disease, thyroid cancer, thyroiditis, T-Lymphocytes, Regulatory, Immune system, Lymphocytes, Tumor-Infiltrating, medicine, Immunology and Allergy, Humans, Thyroid Neoplasms, Thyroid cancer, Cells, Cultured, Original Research, Autoantibodies, Chemistry, Effector, Cancer, FOXP3, Immunotherapy, RC581-607, Middle Aged, medicine.disease, Phenotype, Case-Control Studies, Cancer research, Leukocytes, Mononuclear, Female, Immunologic diseases. Allergy, Tumor Suppressor Protein p53, t effector cells, t regulatory cells, Peptides, CD8, Biomarkers |
| الوصف: | Carcinomas evade the host immune system by negatively modulating CD4+ and CD8+ T effector lymphocytes through forkhead box protein 3 (FOXP3) positive T regulatory cells’ increased activity. Furthermore, interaction of the programmed cell death 1 (PD1) molecule and its ligand programmed cell death ligand 1 (PDL1) inhibits the antitumor activity of PD1+ T lymphocytes. Immunotherapy has become a powerful strategy for tailored cancer patients’ treatment both in adult and pediatric patients aiming to generate potent antitumor responses. Nevertheless, immunotherapies can generate autoimmune responses. This study aimed to investigate the potential effect of the transformation-related protein 53 (p53) reactivation by a peptide-based inhibitor of the MDM2/MDM4 heterodimer (Pep3) on the immune response in a solid cancer,i.e., thyroid carcinoma frequently presenting with thyroid autoimmunity. In peripheral blood mononuclear cell of thyroid cancer patients, Pep3 treatment alters percentages of CD8+ and CD4+ T regulatory and CD8+ and CD4+ T effector cells and favors an anticancer immune response. Of note that reduced frequencies of activated CD8+ and CD4+ T effector cells do not support autoimmunity progression. In evaluating PD1 expression under p53 activation, a significant decrease of activated CD4+PD1+ cells was detected in thyroid cancer patients, suggesting a defective regulation in the initial activation stage, therefore generating a protective condition toward autoimmune progression. |
| اللغة: | English |
| تدمد: | 1664-3224 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2dc3a13cc478cb8f05238d4932a1d86Test http://europepmc.org/articles/PMC8442659Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....d2dc3a13cc478cb8f05238d4932a1d86 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16643224 |
|---|